Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Share-based Compensation (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Share-based Compensation for 6 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 52.22% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.2 million, a 21.81% increase, with the full-year FY2025 number at $40.2 million, up 21.81% from a year prior.
  • Share-based Compensation was $9.5 million for Q4 2025 at Janux Therapeutics, up from $9.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.4 million in Q3 2024 to a low of $123000.0 in Q1 2021.
  • A 5-year average of $5.9 million and a median of $5.0 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 9064.29% in 2021, then crashed 41.22% in 2025.
  • Janux Therapeutics' Share-based Compensation stood at $2.9 million in 2021, then soared by 42.83% to $4.2 million in 2022, then rose by 6.61% to $4.5 million in 2023, then skyrocketed by 39.44% to $6.3 million in 2024, then soared by 52.22% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Share-based Compensation are $9.5 million (Q4 2025), $9.0 million (Q3 2025), and $11.0 million (Q2 2025).